At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial on the c-Met inhibitor, volitinib, in patients with papillary renal cell carcinoma (pRCC).
pRCC is the second most common subtype of renal cell carcinoma and is associated with poor clinical outcomes. Dr Choueiri describes how molecular approaches help direct current research in this field and how inappropriate c-Met activation in cancer cells may be important in pRCC progression. Volitinib is a novel c-Met inhibitor; this Phase 2 trial is an open-label, global and multicentre evaluation of the efficacy and safety of volitinib in patients with pRCC.
Year of Production: